FDA's Software Monsters: Cybersecurity, Interoperability, Mobile Apps and Home Use 2017

  • November 07, 2017
  • 27 Views
  • 0 Comments
  • 0 Likes
FDA's Software Monsters: Cybersecurity, Interoperability, Mobile Apps and Home Use 2017

 

 

 

Course "FDA's Software Monsters: Cybersecurity, Interoperability, Mobile Apps and Home Use" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.

 

Overview:

 

Software's level of complexity and use is expanding at exponential levels. Likewise, the potential risks to health follow suit. Ransomeware attacks hold your software hostage until you pay hundreds or thousands of dollars. Life supporting and life sustaining healthcare grinds to a halt. Extracting personal healthcare information is another plague that has a huge financial incentive for hackers. Your software is running on thin ice.

The FDA looks at software in one of three ways: Standalone, such as for a mobile app; device-based software used to control a device's performance, or simply electronic records. FDA's risk classification will gradually clarify how it intends to manage the health risks with premarket and postmarket controls. What the FDA did not see was the cancer of cybersecurity attacks, the failure of interoperability, and the explosion in the use of wireless communication and mobile apps.

Inadequate cybersecurity programs and the lack of interoperability for healthcare users pose the greatest threat to any healthcare system. Software exploitations are using more sophisticated approaches and the hackers' programs are readily available on the "dark web."

The increasing sophistication required to protect software programs and have them work with other programs requires progressive software design and software validation considerations. In many instances, validation is limited to the immediate use of the software rather than its environment of use, its performance with other software programs and software hacking. FDA can ask you what you have considered before you take a product to market. Whether your software can survive unscathed is another question. When software causes a problem, fixing the malfunction or "bug" may be more difficult as software becomes more sophisticated, customized by users and placed in a network system. In these kinds of circumstances, it is difficult to decide who is responsible for managing and fixing the software problems, preventing them from recurring. This becomes a major regulatory headache for FDA and generates business-to-business conflicts. When firms are designing and marketing software, they should be mindful of the unknowns that lurk in the future of software regulated as a device by the FDA.

 

Why you should attend:

 

For decades, firms have experienced serious problems with software and have been at a loss to make a well-informed follow up. Software problems represent one of the most common root causes for recalls that are associated with deaths and serious injuries beyond what should be necessary to quantify. FDA sees firms revise software only to create more problems rather than solve them. The infusion pump industry is a classic example that drove FDA to implement a new rigorous paradigm for premarket review and performance criteria evaluation.

The growth of the medical software industry outpaces how FDA's regulatory process is designed. How can you anticipate and defend against the malicious remote hacking and shut down of an insulin infusion pump? In some instances, clinicians have weighed the risk of software failure against the benefits of using a device at all. You need to understand and apply the current provisions that NIST has put forth in recent reports FDA will integrate them into its regulatory oversight of cybersecurity management.

Device software is often used in conjunction with other software-based devices, but their interoperability was never anticipated. Can one software program defeat the performance capability or back up safety features of another software program? When interoperability problems surface, which software manufacturer takes the lead to solve the problem and deal with proprietary software issues?

These are the kinds of issues that will be highlighted during the webinar. The issues require careful consideration even though no obvious answer appears at hand.

 

Topics:

  • FDA's risk-based regulatory strategy
  • Cybersecurity
  • Interoperability
  • National Institute of Standards and Technology
  • Voluntary standards and programs
  • Mobile Apps
  • Premarket software validation and design requirements
  • Postmarket Software recalls

 

Who Will Benefit:

  • Regulatory Affairs
  • Quality Assurance
  • Software Design Engineers
  • Manufacturing
  • Complaint Dept.
  • Hospital Risk Dept.
  • Own label marketers

 

Agenda:

 

Day 1 Schedule

9:00 am - 10:15 am

Lecture 1: FDA authority and regulatory program

  • Types of Software are devices
  • Regulatory strategy
  • Risk classification
  • Office of the National Coordinator (ONC) for Health Information Protection
  • Software regulatory applications
  • FDA Guidance
    • Premarket submissions
    • Paradigms: aeronautics

10:15am - 10:30am Break

10:30 am - 12:00 am

  • Quality System Regulation (QSR)
    • Design verification and validation
    • Voluntary standards
    • Corrective and Prevent Action Plans
  • Voluntary standards
  • Recalls:
    • Service / maintenance / recall.
    • Implementation strategy
  • Corrections and Removals reporting
  • Updates: FDA vs. non-FDA
  • Predictive analytics

12:00 PM - 1:00 PM Lunch

1:00 PM - 2:30 PM

Lecture 2: Interoperability

  • Compatibility by design
    • Hardware
    • Software
  • Labeling
    • Precautions
    • Instructions for use
  • Use of Voluntary Standards

2:30 PM - 2:45 PM Break

2:45 PM - 4:15 PM

  • Proprietary information
  • Failure management / follow up
  • User's vs. manufacturer's legal responsibility
    • System configuration
    • Customization
    • Environment of use
    • Professional

Day 2 Schedule

 

9:00 am - 10:15 am

Lecture 1: Cybersecurity

  • Device vulnerabilities: malfunction and failure
  • Pre-emptive design and evolution
  • Hackers' malware/virus strategy

10:30 am - 10:45 am Break

10:45 am - 12:00 pm

  • Post-event management
    • Corrective and preventive action for software
    • Disclosure to users
    • Reports to the FDA waiver
  • National Institute of Standards and Technology Reports

12:00 PM - 1:00 PM Lunch

1:00 PM - 2:30 PM

Lecture 2: Medical Mobile Applications (mobile apps)

  • Mobile apps defined as a device
  • FDA regulatory strategy and guidance
  • National Institute of Science and Technology Report and Collaboration
  • Updates (FDA vs. non-FDA updates)
    • Criteria for corrective and preventive action deemed recalls
    • Reports of Corrections and Removals
    • Reports of adverse events

2:30 PM - 2:45 PM Break

2:45 PM - 4:30 PM

Lecture 3: Professional vs. lay use / home use

  • Labeling: instructions for use and precautions
  • Environment of use
  • FDA regulation of accessories
  • Federal Communications Commission (FCC) regulation

 

Speaker

Casper Uldriks

ex-FDA Expert and former Associate Center Director of CDRH

 

Casper (Cap) Uldriks brings over 32 years of experience from the FDA. He specializes in the FDA's medical device program as a field investigator, served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. He is recognized as an exceptional and energetic speaker. His comments are candid, straightforward and of practical value. He understands how FDA thinks, operates and where it is headed. Cap is the President of Encore Insight, LLC, a consulting service for FDA matters.

               

 

  Location: Boston, MA Date:  December 7th & 8th, 2017 and Time: 9:00 AM to 4:30 PM

Venue:    Embassy Suites Boston Logan Airport   207 Porter St, Boston, MA 02128, USA

 

 Price:

Price: $1,295.00 (Seminar Fee for One Delegate)

 Register for 5 attendees   Price: $3,885.00 $6,475.00 You Save: $2,590.00 (40%)*

Register for 10 attendees   Price: $7,122.00 $12,950.00 You Save: $5,828.00 (45%)*

Register now and save $200. (Early Bird)

Until October 20, Early Bird Price: $1,295.00 From October 21 to December 05, Regular Price: $1,495.00

 

Sponsorship Program benefits for “Quality Assurance Auditing for FDA Regulated Industry” seminar

At this seminar, world-renowned FDA Regulated Industry subject matter experts interact with CXO’s of various designations. Executives who carry vast experience about FDA Regulated Industry and Experts get down to discussing industry-related best practices, regulatory updates, changes in technologies, and much more relating to FDA Regulated Industry.

As a sponsor of these seminars, you get the opportunity to have your product and company reach out to C-Level executives in FDA Regulatory -related industries and become known among these elite executives and subject matter experts. Apart from being seen prominently at these globally held seminars, you also get talked about frequently in our correspondences with our experts and these participants.

For More Information- https://www.globalcompliancepanel.com/control/sponsorship 

 

Contact us today!

 

NetZealous LLC DBA GlobalCompliancePanel

john.robinson@globalcompliancepanel.com  

support@globalcompliancepanel.com 

Toll free: +1-800-447-9407

Phone: +1-510-584-9661

 Website: http://www.globalcompliancepanel.com

 

Registration Link - http://www.globalcompliancepanel.com/control/globalseminars/~product_id=901106SEMINAR?machprinciple-December-2017-SEO

 

Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanel/

Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/

Follow us on Twitter: https://twitter.com/GCPanel

 


Leave a Comment